ORIGINAL RESEARCH ARTICLE ORIGINAL RESEARCH ARTICLE BACKGROUND: Human pluripotent stem cell (hPSC)-derived endothelial cells (ECs) have limited clinical utility because of undefined components in the differentiation system and poor cell survival in vivo. Here, we aimed to develop a fully defined and clinically compatible system to differentiate hPSCs into ECs. Furthermore, we aimed to enhance cell survival, vessel formation, and therapeutic potential by encapsulating hPSC-ECs with a peptide amphiphile (PA) nanomatrix gel.
I
schemic cardiovascular diseases are the most common cause of morbidity and mortality in industrialized countries. As the loss of vascular supply is a main pathophysiologic feature of these diseases, therapies restoring this fundamental deficit should target growth of blood vessels, for which endothelial cells (ECs) play a crucial role.
Recently, human pluripotent stem cells (hPSCs), which include human embryonic stem cells (hESCs) and human-induced pluripotent stem cells (hiPSCs), have emerged as a promising candidate for vascular regeneration therapy because they have unquestionable EC differentiation capacity. [1] [2] [3] [4] [5] However, there are 2 significant hurdles in their path toward clinical applicability: development of a clinically compatible system for generating ECs and low retention and survival of cells in vivo. In particular, despite its critical importance for clinical applicability, measures to increase cell survival in ischemic tissues were not previously addressed.
For hPSC-ECs to be used for clinical applications, the following criteria at least must be met. hPSCs need to be differentiated under defined conditions free of xenogeneic components. The culture system should yield ECs at high efficiency, which must be verified in multiple cell lines. The differentiated ECs should be highly pure and must be functional in vivo. Their therapeutic effects should be confirmed in animal models of cardiovascular disease. Finally, tumorigenic potential or adverse effects of implanted cells must be ruled out by long-term follow-up. Although other studies have investigated 1 or several aspects of these points, no studies have addressed all these issues, which has precluded clinical translation of hP-SC-derived ECs.
Moreover, low survival of transplanted cells in ischemic tissues poses a critical barrier for cell therapy even with hPSC-derived cells. When adult cells were injected into ischemic hearts, >50% of the cells disappeared immediately, and virtually all cells were lost within a month. 6, 7 The survival of hESC-ECs injected into ischemic hearts was not much different: <10% of the injected cells survived at 1 week, and ≤1% remained at 8 weeks. 8 hPSC-derived cardiomyocytes showed poor survival in ischemic hearts, with most of them disappearing usually within a month. 9 Similar trends were observed when cells were injected into a hind-limb ischemia (HLI) model. Monitoring of cell survival with bioluminescent imaging (BLI) demonstrated that mesenchymal stem cells disappeared by 6 days 10 or 20 days 11 after cell transplantation. Survival of hPSC-ECs in a HLI model was reported by only 1 study, which showed no detectable bioluminescence signals after 14 days. 12 These studies question the advantages of using hPSC-derived ECs over adult cells if they function through short-term paracrine effects without durable vascular incorporation. Moreover, because of the short-term cell survival, there has been no way to investigate how hPSC-ECs behave and contribute to vessel formation in ischemic tissues.
To overcome low cell survival in vivo, various biomaterial-based strategies have been attempted. [13] [14] [15] [16] [17] However, to date, no studies have investigated the effects of biomaterial-mediated delivery of hPSC-ECs in any cardiovascular disease models. In this study, we investigated whether biomaterial-mediated delivery of hPSCECs could prolong cell survival and thereby improve therapeutic neovascularization and whether, as a result of increased cell survival, we could elucidate previously unknown behaviors of hPSC-ECs in vivo.
We selected a novel injectable self-assembled peptide amphiphile (PA) nanomatrix gel, which has emerged as a highly promising biomaterial to enhance cell engraftment and survival. 16, 18, 19 PAs are peptidebased molecules consisting of a short hydrophobic sequence linked to a hydrophilic, bioactive peptide sequence that self-assemble into high-aspect-ratio nanofibers at physiological conditions. By closely mimicking the physical and biochemical complexity of the natural extracellular matrix, PAs provide nourishing and protecting microenvironments for cells. 16, 18, 19 For this study, we generated extracellular matrix-mimick-
Clinical Perspective
What Is New?
• We developed a novel, fully defined cell culture system to generate highly enriched endothelial cells (ECs) from human pluripotent stem cells (hPSCs) that is compatible with clinical application.
• The hPSC-derived ECs showed genuine EC characteristics and proangiogenic activities and exerted favorable therapeutic effects for repairing limb ischemia.
• Encapsulation of hPSC-derived ECs in the biocompatible extracellular matrix-mimicking peptide amphiphile nanomatrix gel improved long-term survival of hPSC-ECs in an ischemic environment, showing the longest survival of hPSC-ECs in ischemic tissue (10 months) and improved vessel-forming properties.
What Are the Clinical Implications?
• The hPSC-ECs will be useful for treatment of ischemic cardiovascular disease, drug discovery, and pathophysiological investigation of vascular diseases.
• The peptide amphiphile nanomatrix gel-mediated transplantation of hPSC-ECs can serve as a novel platform for cell-based therapy for cardiovascular disease and investigation of long-term behavior of hPSC-ECs.
Circulation. ORIGINAL RESEARCH ARTICLE ing PA nanomatrix gel (RGDS) by incorporating cell adhesive ligand Arg-Gly-Asp-Ser (RGDS) and matrix metalloprotease-2-degradable sequence Gly-Thr-AlaGly-Leu-Ile-Gly-Gln (GTAGLIGQ) into the PA ( Figure I in the online-only Data Supplement). 16, 18, 19 RGDS, a fibronectin-derived cell adhesive ligand, is incorporated into PAs to promote cell adhesion and survival. The incorporation of matrix metalloprotease-2-degradable sequences allows cell-mediated degradation of the nanomatrix gel and migration of encapsulated cells into surrounding tissues.
In this study, we developed a fully defined, clinically compatible cell culture system that can generate purified, functional, and therapeutically effective ECs. Next, we encapsulated hPSC-ECs within the nanomatrix gel and transplanted them into experimental HLI. These encapsulated hPSC-ECs remained engrafted for >10 months in ischemic tissues, and compared with bare hPSC-ECs, they exerted higher and prolonged neovascularization and showed better vascular regenerative capacity. Particularly, this study for the first time demonstrated long-term in vivo behavior of hP-SC-ECs in ischemic tissues and revealed sustained and dynamic incorporation of engrafted hPSC-ECs into the host vessels. This platform can serve as an effective modality for treating cardiovascular disease and can be used to investigate long-term behavior of the implanted cells.
METHODS
The use of hESCs was approved by the Emory University Human Embryonic Stem Cell Research Oversight Committee, and all animal protocols were approved by the Emory University Institutional Animal Care and Use Committee.
hPSC Culture and Differentiation
The hESCs (H1, H7, and H9) and hiPSCs (BJ1 and PGP1 obtained from Dr George Daley) were cultured in mTeSR 1 (STEMCELL Technologies) on 5% Matrigel at 37°C with 5% CO 2 . 20 For directed differentiation, enzymatically dissociated clumps of hPSCs (lower than passage 60) were cultured on 0.01% collagen-coated plates in DMEM/F12 including 20% Serum Replacement with or without the addition of specific differentiation factors for 7 to 10 days ( Figure 1A ).
Quantitative Reverse TranscriptionPolymerase Chain Reaction
Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) assay was performed as described previously. 7, 21 In brief, total RNA was isolated from cells with RNeasy (Qiagen, Venlo, Netherlands) according to the manufacturer's instructions. Extracted RNA was reverse-transcribed with Taqman Reverse Transcription Reagents (Applied Biosystems, Foster, CA) according to the manufacturer's instructions. The synthesized cDNA was subjected to qRT-PCR with specific primers and probes (Table I in the onlineonly Data Supplement). Quantitative assessment of RNA levels was performed with an ABI PRISM 7500 Sequence Detection System (Applied Biosystems). Relative mRNA expression normalized to GAPDH expression was calculated as previously described.
21
Magnetic Activated Cell Sorting hPSCs were cultured on collagen coated plates for an additional 14 days. For sorting of CDH5 + with magneticactivated cell sorting, differentiated hPSCs were incubated with APC-conjugated mouse anti-human CDH5/CD144 (17-1449-42, eBioscience). After washing, the cell pellet was incubated with anti-APC beads (120-001-265, Miltenyi Biotec) and subjected to magnetic-activated cell sorting (Miltenyi Biotec).
Fabrication of the Nanomatrix Gel
Two PAs, C 16 -GTAGLIGQRGDS (PA-RGDS) and C 16 -GTAGLIGQS (PA-S), were synthesized via Fmoc chemistry with an AAPPTec Apex 396 peptide synthesizer as previously described. 16, 18, 19 The peptides were then alkylated at the N-termini via two 12-hour reactions with palmitic acid in the presence of a mixture of o-benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate and diisopropylethylamine dissolved in dimethylformamide. This was followed by cleavage from the resin and deprotection for 3 hours with a 40:1:1:1 cocktail of trifluoroacetic acid, deionized water, triisopropylsilane, and anisole. The collected samples were subjected to rotary evaporation to remove excess trifluoroacetic acid, precipitated in diethyl ether, and lyophilized. Successful synthesis of the PAs was confirmed via matrix-assisted laser desorption ionization time-of-flight mass spectrometry.
Stock solutions of the 2 PAs, PA-RGDS and PA-S (2% [weight/volume]) were individually prepared by dissolving lyophilized PA in distilled water and adjusting the pH to 7 with 1 mol/L sodium hydroxide (NaOH). The 2 PA solutions were then mixed in a 1:1 molar ratio, and self-assembly into 3-dimensional hydrogels was induced by combining 50 μL PA solution with a mixture containing 15 μL of 0.1 mol/L CaCl 2 and 25 μL cell suspension 18, 19 Intracellular Nitric Oxide Detection hPSC-derived ECs and human umbilical vein ECs (HUVECs) were treated with 4-amino-5-methylamino-2′,7′-difluorofluorescein (DAF-FM) diacetate (Invitrogen, Carlsbad, CA) for 1 hour. 22 After the excess probe was removed, cells were incubated for an additional 20 minutes to allow complete de-esterification of the intracellular DAF-FM diacetate to the nonpermeable and nonfluorescent DAF-FM, which is converted to the highly fluorescent triazol form in the presence of nitric oxide (NO). The fluorescence images were captured from at least 5 randomly selected cells per dish under fluorescence microscopy. The relative levels of intracellular NO were determined by quantifying the fluorescence intensity of DAF-FM with ImageJ software. ORIGINAL RESEARCH
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Transplantation of the Cells Into Ischemic Hind Limb
We performed HLI surgery and cell implantation as described previously. 21, 23 Briefly, a ligation was made around the femoral artery, and large branches were cauterized in 8-to 12-weekold athymic male nude mice (Foxn1 nu ) (Harlan). Mice were randomly assigned to 7 groups: surgery only, medium, nanomatrix gel, HUVECs, hPSC-ECs, and HUVECs or hPSC-ECs encapsulated within the nanomatrix gel. In all cases, 2×10 5 cells were used. Immediately after the surgery, medium or bare cells were injected and encapsulated cells were implanted into hind-limb muscles. For histological studies, cells were prelabeled with chloromethylbenzamido (CellTracker CM-DiI) for tracking the cells before cell implantation. 7, 21, 24 According to Institutional Animal Care and Use Committee guidelines, mice were kept in small cages (up to 5 animals in each cage) and fed sterile food and water. Pre-established exclusion criteria for surgery and follow-up analyses included systemic diseases, toxicity, respiratory distress, interference with eating and drinking, and substantial weight loss (>15%). During the study period, most of animals appeared to be in good health and were included in the appropriate analysis.
Blood Flow Measurement in Ischemic Hind Limb
Blood flow of the hind limb was measured with a laser Doppler perfusion imager (Moor Instruments Ltd) before and after surgery and every week for 4 weeks. 21 Mean values of perfusion were calculated from the stored digital color-coded images. The blood flow level of the ischemic (left) limb was normalized to the nonischemic (right) limb to avoid data variations caused by ambient light and temperature.
Statistical Analysis
Statistical analyses and calculation of sample size were performed with Prism 5 software (GraphPad Software, La Jolla, CA). All data demonstrated a normal distribution and similar variation between groups; hence, only parametric tests were required. In each experiment, the sample size was determined from the expected difference and estimated SD, with 2-sided significance of 0.05 and power of 0.90. Statistical analyses were performed with the standard unpaired Student t test for comparisons between 2 groups and an appropriate ANOVA followed by multiple comparisons with the Tukey method for comparison among >2 groups, as indicated in each figure legend. qRT-PCR and cell biological assays were performed at least in triplicate with 3 to 6 independent experiments. Flow cytometry analysis was performed with 3 to 5 independent samples. For the HLI studies, the estimated minimal number for having meaningful difference at 4 weeks is 5, so we included 5 to 12 animals in each group. Investigators were blinded to the assessment of the analyses of cell, animal, and histological experiments when comparison between the groups was made. All data were presented as mean±SEM. Values of P<0.05 were considered to denote statistical significance.
RESULTS
Generation of hPSC-Derived ECs via a Clinically Compatible System
We developed a clinically compatible stepwise protocol that follows endothelial development ( Figure 1A ). To develop a fully defined system, KnockOut Serum Replacement was substituted for animal serum and feeder cells. As a first step, we compared 2 coating materials, collagen and Matrigel, and induced differentiation of hPSCs into the mesodermal lineage using CHIR99021, a glycogen synthase kinase 3β inhibitor that mimics Wnt activation. 25 hESCs (H9) were plated onto dishes coated with 0.01% collagen or 10% Matrigel and were cultured for 3, 5, and 7 days in hESC medium with or without 3 μmol/L CHIR99021. Real-time RT-PCR (qRT-PCR) showed that T (also known as Brachyury) and KDR transcripts were most highly expressed in conditions using collagen coating and CHIR99021 treatment for 3 days ( Figure To enrich endothelial lineage cells, we sorted the differentiated cells at day 14 for CDH5 with the magnetic-labeled cell separation system (magnetic-activated cell sorting). The sorted CDH5 + cells exhibited 3-to 8-fold higher mRNA expression of KDR, NOS3 (eNOS),
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and VWF compared to CDH5 − cells ( Figure 1E ). Immunocytochemistry demonstrated that almost all CDH5 + cells expressed vWF and CDH5 ( Figure 1F ). The hPSC-CDH5 + cells showed typical cobblestone-like EC morphology and produced NO detected by DAF-FM diacetate ( Figure 1G) . Quantitatively, the DAF-FM intensities of the 2 lines of hPSC-CDH5 + cells were similar to that of HUVECs. These CDH5 + cells formed tubular structures in Matrigel and showed uptake of DiI-acetylated low-density lipoprotein and binding to UEA-1 lectin ( Figure 1H ). In agreement with the in vitro results, we found colocalization of the injected cells with isolectin B4 (ILB4)-positive vessels in vivo using a Matrigel plug assay ( Figure 1I ). These data suggest that the sorted hPSC-CDH5 + cells are highly enriched functional endothelial lineage cells.
Proangiogenic Properties of hPSCDerived ECs
To determine angiogenic activity of the sorted cells, we first measured expression of proangiogenic factors in presorted and postsorted cells. qRT-PCR showed that mRNA expression of VEGFA, IGF1, ANGPT1, and FGF2 was significantly higher in the CDH5 + cells compared with the CDH5 − cells or unsorted cells (Figure 2A) . Next, we conducted cell migration and tubeformation assays using conditioned media (CM) collected from cultured CDH5 + cells or HUVECs. In the cell migration assay with Boyden chamber, the number of migrated ECs was significantly higher in the CDH5 + cell group compared with the HUVEC group ( Figure 2B ). For the tube formation assay, ECs were cultured on Matrigel-coated plates, and the above 2 CM were added. Tube length and branches assessed 8 hours later were significantly higher in the CDH5 + -CM-treated group compared with the HUVEC-CMtreated group ( Figure 2C ). These data indicate potent proangiogenic properties of hPSC-CDH5 + cells.
Cytoprotection of hPSC-ECs Under Oxidative Stress by the Nanomatrix Gel Encapsulation
We then investigated whether the PA-RGDS nanomatrix gel supports the viability of hPSC-derived ECs in regular culture conditions. hPSC-derived ECs were encapsulated within the nanomatrix gel ( Figure 3A ) and cultured for 7 days under normal EC culture conditions. Live/ dead staining at day 7 demonstrated that 96.5±1.3% encapsulated hESC-ECs were viable ( Figure 3B ). Next, we determined whether hPSC-ECs can survive under oxidative stress, which is a major cause of low cell survival in ischemic tissues. 14 We thus exposed hPSCECs encapsulated within the nanomatrix gel to a high concentration of H 2 O 2 (100 μmol/L). Live/dead staining demonstrated that viability was 8.2 times better when hPSC-ECs were encapsulated than not ( Figure 3C and 3D). These results indicate that encapsulation of hPSCECs within the nanomatrix gel can promote EC survival under oxidative stress.
Degradation Kinetics of the Nanomatrix Gel In Vivo
To examine the in vivo degradation of the nanomatrix gel, the gel was prelabeled with CM-DiI, a red fluorescent dye ( Figure VIIA in the online-only Data Supplement). We surgically induced HLI in nude mice, and the nanomatrix gel was implanted into the ischemic hind limb. The mice were euthanized at 1, 3, or 6 weeks after injections, and the hind-limb tissues were harvested. Through histological evaluation under confocal microscopy, we found that the DiI-labeled nanomatrix gel was gradually decreased in muscle tissues over time and was almost completely degraded at 6 weeks (Figure VIIB in the online-only Data Supplement).
Therapeutic Effects of hPSC-ECs Encapsulated Within the Nanomatrix Gel on HLI
To determine the therapeutic effects of hPSC-derived ECs encapsulated within the nanomatrix gel on ischemic disease, we used an HLI model. We surgically induced HLI in nude mice and transplanted hPSC (BJ1-hiPSC) ECs (2×10 5 ) encapsulated with or without the nanomatrix gel, HUVECs (2×10 5 ) with or without the nanomatrix gel, the nanomatrix gel only, or CM into hind-limb muscle. Laser Doppler perfusion image analysis demonstrated that the hPSC-EC and hPSC-EC/ nanomatrix gel group showed higher blood flow at 2, 3, and 4 weeks compared with other groups such as no treatment (surgery only), medium, the nanomatrix gel only, and HUVECs with or without the nanomatrix gel ( Figure 4A and 4B) . Moreover, the hPSC-EC/nanomatrix gel group showed higher blood flow than the bare hPSC-EC-group at 4 weeks. We further conducted similar experiments with another cell line, H9 hESCs, and found similar results (data not shown). We next determined the density of vessels and muscles in tissues harvested at 4 weeks that were systemically perfused with FITC-conjugated ILB4. The functional vascular density was again higher in the hPSC-EC group compared with the other groups when omitting the encapsulated hPSC-EC group. However, when the encapsulated and bare hPSC-EC groups were compared, the vascular density was significantly higher in the encapsulated group ( Figure 4C and 4D) . Furthermore, the muscle density was significantly higher in the hPSC-EC/nanomatrix gel group compared with the other groups ( Figure 4E and  4F) . Taken together, these results indicate that encapsulation of hPSC-ECs within the nanomatrix gel is most effective for repairing limb ischemia and augments functional and structural neovascularization. -cells, and hPSC-CDH5 + cells measured by quantitative reverse transcriptionpolymerase chain reaction. Data are presented as mRNA expression relative to GAPDH. Three independent experiments, each with technical triplicates. *P<0.05, 1-way ANOVA followed by multiple comparisons with the Tukey method. B, and C, Sorted hPSC-CDH5 + cells and human umbilical vein endothelial cells (HUVECs) were cultured in M199 media, and the conditioned media (CM) of CDH5 + cells and HUVECs were collected and used for migration (B) and tube formation (C) assays. M199 media containing 1% FBS was used as a negative control. Representative examples from H9 are shown. *P<0.05, 1-way ANOVA followed by multiple comparisons with the Tukey method (n=6). hESC indicates human embryonic stem cell.
Prolonged Engraftment of hPSC-ECs Encapsulated Within the Nanomatrix Gel in Ischemic Tissues
An important issue that was not addressed in previous studies is the long-term temporospatial behavior of the implanted hPSC-ECs in ischemic disease models. Thus, we monitored the fate of implanted cells by BLI over 21 weeks and histologically for 10 months ( Figure 5 ). For BLI studies, hPSC-ECs were transduced with a reporter gene consisting Fluc-TdTomato ( Fluc+TdTomato+ hPSC-CDH5 + ) before transplantation. 26, 27 We confirmed that >90% of the transduced hPSC-ECs expressed TdTomato by fluorescence microscopy and flow cytometry ( Figure  VIIIA and VIIIB in the online-only Data Supplement). We then optimized the exposure time to detect bioluminescence signals after encapsulating hPSC-ECs within the nanomatrix gel ( Figure VIIIC in the online-only Data Supplement) and used these conditions for in vivo BLI experiments ( Figure 5A ). In mice receiving hPSC-ECs only, bioluminescence signals increased over 3 days but dramatically reduced thereafter, approaching an undetectable level at week 3. However, in mice receiving nanomatrix gel-encapsulated hPSC-ECs, the bioluminescence signals were gradually increased over 1 week, presumably because degradation of the nanomatrix gel over this period allowed quicker penetration of luciferin into the nanomatrix gel and hPSC-ECs. These BLI signals were well maintained between 2 and 14 weeks but rapidly decreased to a minimally detectable level by 21 weeks. From week 1 on, the BLI signals were consistently higher in the encapsulated group than in the nonencapsulated group ( Figure 5A and 5B).
For histological analysis, hPSC-ECs were prelabeled with a red fluorescent dye, DiI, and both nanomatrix gel-encapsulated and bare hPSC-ECs were transplanted into the hind limb after HLI surgery. We harvested muscle tissues at 2 weeks, 4 weeks, 2 months, and 10 months and performed immunohistochemistry ( Figure 5C ). Confocal microscopic examination of the tissues demonstrated that the number of engrafted cells were gradually decreased over 10 months in both groups, but at all measured points, it was significantly higher in the nanomatrix gel-encapsulated group compared with the bare hPSC-EC group ( Figure 5C and 5D ). Taken together, encapsulation of hPSC-derived ECs within the nanomatrix gel substantially increased engraftment and long-term survival of transplanted hPSCECs in ischemic hind limbs.
In Vivo Neovascularization of Nanomatrix Gel-Encapsulated hPSC-ECs
To investigate angiogenic effects of hPSC-EC transplantation, we performed qRT-PCR with muscles harvested at 2 and 4 weeks. We compared the expression of 6 representative angiogenic genes (Vegfa, Angpt1, Fgf2, Igf1, Ccl2 , and Pdgfb) between mice receiving the nanomatrix gel-encapsulated hPSC-ECs, hPSC-ECs, nanomatrix gel-encapsulated HUVECs, HUVECs, or the nanomatrix gel only. First, we compared mRNA expression between the hPSC-EC group and control groups (HUVEC, nanomatrix gel-encapsulated HUVECs, or nanomatrix gel; Figure 6A ). The hPSC-EC group showed higher expression of Vegfa and Angpt1 compared with controls at 2 weeks and Mcp-1 at 4 weeks. Next, we compared mRNA expression between the nanomatrix gel-encapsulated hPSC-EC group and the bare hPSC- EC group. At both 2 and 4 weeks, expression of all the genes except Angpt1 (2 weeks) and Ccl2 (4 weeks) was significantly higher in the encapsulated hPSC-EC group compared with bare hPSC-ECs. These data indicate that although bare hPSC-EC injection increased limited angiogenic and arteriogenic factors for 2 to 4 weeks, the encapsulated hPSC-ECs increased most representative angiogenic, arteriogenic, and cytoprotective factors more robustly and for >4 weeks.
Next, we examined vasculogenic effects or direct contribution of hPSC-ECs to vessel formation over 10 months via histological analyses. For these experiments, FITC-ILB4 was systemically injected before death to identify functional endothelium. Confocal microscopic examination of tissues demonstrated that engrafted hPSC-ECs were more frequently observed near the vasculature over time (Figure 6B through 6D) . Quantitatively, the proportion of perivascularly localized hPSC-ECs per total engrafted hPSC-ECs was gradually increased over time in both encapsulated and bare hP-SC-EC injected groups; however, the absolute numbers were significantly higher in the encapsulated hPSC-EC group ( Figure 6C and 6D) . Moreover, from 4 weeks to 10 months after implantation, some of the engrafted 
A,
Fluc+Tomato+ hPSC-ECs, alone or encapsulated within nanomatrix gel, were transplanted into ischemic hind limbs and were tracked noninvasively by bioluminescent imaging (BLI) over 21 weeks. Rainbow bar refers to the threshold to discriminate background noise from a positive BLI signal. B, Quantitative analysis of BLI from ischemic hind limbs implanted with bare or nanomatrix gel-encapsulated hPSC-ECs (n=3 per group). *P<0.05, repeated-measures ANOVA followed by multiple comparisons with the Tukey method. C, Confocal microscopic images of muscle sections implanted with bare or nanomatrix gel-encapsulated hPSC-ECs taken at indicated time points over 10 months. Representative examples from BJ1 are shown. D, Quantification of engrafted cell density (n=6). *P<0.05, 2-way ANOVA followed by multiple comparisons with the Tukey method. Last, we examined temporal changes in the incorporation of hPSC-ECs into the vessels. In the unencapsulated hPSC-EC group, very few hPSC-ECs were incorporated into vessels at 1 week. However, the proportion of hPSC-EC-incorporated vessels (DiI Figure 6I ). In the nanomatrix gel-encapsulated hPSC-EC group, the proportion was similarly low at 1 week; however, it progressively increased between 1 and 10 months, and at each time point (1, 2, 10 months), it was significantly higher compared with the unencapsulated group ( Figure 6B , bottom and Figure 6F through 6I). At 10 months, the proportion of hPSC-ECs incorporated into vessels reached 45.9% (white arrows in Figure 6H and 6I and Video I in the online-only Data Supplement), and 78.6% of engrafted or remaining hPSC-ECs were completely incorporated into vessels (white arrows in Figure 6H and 6J). It is notable that vessels incorporated with multiple hPSC-ECs were observed, which was rarely seen at other time points. Moreover, some of the unincorporated hPSC-ECs were linearly or curvilinearly aligned like vessels parallel to or continuous with host vessels (yellow dotted lines in Figure 6H and Figure IX in the online-only Data Supplement), and a part of them were faintly stained positive for ILB4 (cyan arrowheads in the yellow dotted lines in panel 9 in Figure 6H and Figure IXB in the online-only Data Supplement), indicating that hPSC-ECs play a guiding role for new vessel formation. Together, these data suggest that engrafted hPSC-ECs were initially moving toward vessels and gradually incorporated into vessels, and the nanomatrix gel, by enabling long-term cell survival, allowed sustained vasculogenic effects of hPSC-ECs.
We stained tissues with the endodermal marker α-fetoprotein and ectodermal markers SOX1 and Nestin and did not detect cells differentiated into other lineages (data not shown). Gross and microscopic examination showed no discernible tumors after injection with hPSC-ECs in 88 animals. Together, these data suggest that implantation of hPSC-ECs encapsulated with PA-RGDS recovered blood flow through enhancement of cell retention and neovascularization within ischemic hind limb.
DISCUSSION
This study addressed 2 major roadblocks for cardiovascular cell therapy: generating clinically compatible, high-purity, therapeutically effective, and safe hPSC-derived ECs and enabling long-term survival of hPSC-ECs in ischemic tissue via encapsulation within the nanomatrix gel, thus enhancing their therapeutic effects. Furthermore, this study uncovered long-term in vivo behavior of hPSC-ECs in ischemic tissues: sustained and dynamic incorporation of engrafted hPSC-ECs into the host vessels and a guiding role of hPSC-ECs for new vessel formation.
Using 2 molecules, CHIR99021 and DLL4, and sorting with CDH5, we established a highly efficient EC differentiation system. Of note, the purified hPSC-CDH5 + cells produced NO, a critical marker for functional ECs, which was not demonstrated in previous studies. Our system and the resultant hPSC-ECs have unique characteristics that favor clinical translation. First, this protocol used fully defined conditions and showed no cell line variability among the lines we tested. Because a main advantage of hiPSC technology is its potential for autologous therapy, a protocol that can be universally applicable is required. Second, hPSC-derived ECs generated by our protocol demonstrated proangiogenic potential and direct vessel-forming effects. These dual characteristics have respective benefits; each contributed to therapeutic neovascularization at different time points. Third, the implanted hPSC-ECs, even encapsulated, did not induce tumorigenic or other side effects during long-term follow-up. The PA nanomatrix gel dramatically increased survival of hPSC-ECs and induced robust and long-standing vascular regenerative effects. The unique structural and functional characteristics of the nanomatrix gel provide important insight into how encapsulated hPSC-ECs exert therapeutic effects for tissue ischemia. Our results suggest that initially the extracellular matrix-mimicking structure incorporating adhesive ligands allows easy adhesion of the nanomatrix gel with host extracellular matrix, stabilization of encapsulated hPSC-ECs, and transport of nutrients and growth factors by diffusion, thereby promoting the viability of the encapsulated hPSC-ECs and exerting proangiogenic effects on the host cells during the critical early phase of cell survival. Degradation of the nanomatrix gel then exposes and allows migration of encapsulated hPSC-ECs into ischemic areas and structural contribution of hPSC-ECs to vessel formation. This vasculogenic effect gradually becomes the main role for vascularization.
Long-term retention of hPSC-ECs via the nanomatrix gel allowed us to examine previously unreported temporal reorganization of engrafted cells and their relation to new vessel formation. First, we discovered that it takes several weeks for a majority of implanted cells to migrate toward vessels and to directly incorporate into vessels. As reported in earlier studies 5, 28 and ours, when hPSCECs alone were implanted, most cells died within several weeks, so most effects are paracrine. However, when hP-SC-ECs were delivered within the nanomatrix gel, many cells were protected and thus had an opportunity to migrate toward vascular areas later. Second, the proportion of engrafted hPSC-ECs incorporated into the vessels increased steadily over 10 months. Initially, hPSC-ECs were more localized in the perivascular areas; however, during host vessel reorganization and new vessel formation, more hPSC-ECs were incorporated into the vessels. At 2 months, there were more engrafted cells and more perivascularly localized cells in the nanomatrix gel-positive cell group compared with the bare cell group, mainly as a result of higher survival of implanted cells. Between 2 to 10 months, these surplus perivascularly localized hPSCECs appeared to be more incorporated into the vessels during the vessel growth and remodeling as shown in Figure 6I and 6J. Thus, at 10 months, the number of perivascularly localized cells in the nanomatrix gel group was substantially decreased to the level of bare cell group. Why the number of the perivascularly localized cells is similar remains to be determined. We can speculate that a certain balance is needed between the number of perivascularly localized cells per vessels or that these similar numbers might be just coincidental. To address this more appropriately, an even longer follow-up is needed. Third, long-term engraftment is a critical factor for ongoing vasculogenesis by hPSC-ECs. Third, hPSC-ECs showed a guiding role for vessel growth, which enables multiple cellular incorporation during vessel formation. This is an unprecedented and the most notable finding in our study. Even at 10 months, we observed a guiding role and sustained and robust vessel growth, attributed to surviving hPSC-ECs. These data offer the very optimistic prospect that hPSC-ECs can be useful for clinical therapy for ischemic vascular disease because most human cardiovascular diseases are chronic and require sustained vessel formation for effective treatment.
CONCLUSIONS
We developed for the first time a cell therapy with nanomatrix gel-encapsulated hPSC-ECs and demonstrated its therapeutic effects and safety. Because both the cell generation protocol and the nanomatrices are biocompatible, this platform can represent a highly effective therapeutic option for ischemic vascular disease.
Furthermore, these hPSC-ECs and this bioengineered platform can help investigate the long-term fate of the implanted cells, disease investigation, and drug discovery.
